Literature DB >> 23860985

Vasopressin, steroids, and epinephrine and neurologically favorable survival after in-hospital cardiac arrest: a randomized clinical trial.

Spyros D Mentzelopoulos1, Sotirios Malachias, Christos Chamos, Demetrios Konstantopoulos, Theodora Ntaidou, Androula Papastylianou, Iosifinia Kolliantzaki, Maria Theodoridi, Helen Ischaki, Dimosthemis Makris, Epaminondas Zakynthinos, Elias Zintzaras, Sotirios Sourlas, Stavros Aloizos, Spyros G Zakynthinos.   

Abstract

IMPORTANCE: Among patients with cardiac arrest, preliminary data have shown improved return of spontaneous circulation and survival to hospital discharge with the vasopressin-steroids-epinephrine (VSE) combination.
OBJECTIVE: To determine whether combined vasopressin-epinephrine during cardiopulmonary resuscitation (CPR) and corticosteroid supplementation during and after CPR improve survival to hospital discharge with a Cerebral Performance Category (CPC) score of 1 or 2 in vasopressor-requiring, in-hospital cardiac arrest. DESIGN, SETTING, AND PARTICIPANTS: Randomized, double-blind, placebo-controlled, parallel-group trial performed from September 1, 2008, to October 1, 2010, in 3 Greek tertiary care centers (2400 beds) with 268 consecutive patients with cardiac arrest requiring epinephrine according to resuscitation guidelines (from 364 patients assessed for eligibility).
INTERVENTIONS: Patients received either vasopressin (20 IU/CPR cycle) plus epinephrine (1 mg/CPR cycle; cycle duration approximately 3 minutes) (VSE group, n = 130) or saline placebo plus epinephrine (1 mg/CPR cycle; cycle duration approximately 3 minutes) (control group, n = 138) for the first 5 CPR cycles after randomization, followed by additional epinephrine if needed. During the first CPR cycle after randomization, patients in the VSE group received methylprednisolone (40 mg) and patients in the control group received saline placebo. Shock after resuscitation was treated with stress-dose hydrocortisone (300 mg daily for 7 days maximum and gradual taper) (VSE group, n = 76) or saline placebo (control group, n = 73). MAIN OUTCOMES AND MEASURES: Return of spontaneous circulation (ROSC) for 20 minutes or longer and survival to hospital discharge with a CPC score of 1 or 2.
RESULTS: Follow-up was completed in all resuscitated patients. Patients in the VSE group vs patients in the control group had higher probability for ROSC of 20 minutes or longer (109/130 [83.9%] vs 91/138 [65.9%]; odds ratio [OR], 2.98; 95% CI, 1.39-6.40; P = .005) and survival to hospital discharge with CPC score of 1 or 2 (18/130 [13.9%] vs 7/138 [5.1%]; OR, 3.28; 95% CI, 1.17-9.20; P = .02). Patients in the VSE group with postresuscitation shock vs corresponding patients in the control group had higher probability for survival to hospital discharge with CPC scores of 1 or 2 (16/76 [21.1%] vs 6/73 [8.2%]; OR, 3.74; 95% CI, 1.20-11.62; P = .02), improved hemodynamics and central venous oxygen saturation, and less organ dysfunction. Adverse event rates were similar in the 2 groups. CONCLUSION AND RELEVANCE: Among patients with cardiac arrest requiring vasopressors, combined vasopressin-epinephrine and methylprednisolone during CPR and stress-dose hydrocortisone in postresuscitation shock, compared with epinephrine/saline placebo, resulted in improved survival to hospital discharge with favorable neurological status. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00729794.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23860985     DOI: 10.1001/jama.2013.7832

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  57 in total

1.  Cardiac resuscitation: A new gold-standard medical therapy for CPR in patients with in-hospital cardiac arrest?

Authors:  Alexandra Roberts
Journal:  Nat Rev Cardiol       Date:  2013-08-06       Impact factor: 32.419

Review 2.  Critical care medicine 2013: a review and prospect.

Authors:  Wei Huang
Journal:  J Thorac Dis       Date:  2013-12       Impact factor: 2.895

Review 3.  Advances in clinical studies of cardiopulmonary resuscitation.

Authors:  Shou-Quan Chen
Journal:  World J Emerg Med       Date:  2015

4.  Glycocalyx degradation leads to blood-brain barrier dysfunction and brain edema after asphyxia cardiac arrest in rats.

Authors:  Jiajia Zhu; Xing Li; Jia Yin; Yafang Hu; Yong Gu; Suyue Pan
Journal:  J Cereb Blood Flow Metab       Date:  2017-08-21       Impact factor: 6.200

5.  Vasopressin, steroids and epinephrine and neurologically favourable survival after in-hospital cardiac arrest.

Authors: 
Journal:  J Intensive Care Soc       Date:  2014-12-12

6.  Guidelines for the diagnosis and management of critical illness-related corticosteroid insufficiency (CIRCI) in critically ill patients (Part II): Society of Critical Care Medicine (SCCM) and European Society of Intensive Care Medicine (ESICM) 2017.

Authors:  Stephen M Pastores; Djillali Annane; Bram Rochwerg
Journal:  Intensive Care Med       Date:  2017-10-31       Impact factor: 17.440

Review 7.  [Inhospital resuscitation : Decisive measures for the outcome].

Authors:  M P Müller; T Jantzen; S Brenner; J Gräsner; K Preiß; J Wnent
Journal:  Anaesthesist       Date:  2015-04       Impact factor: 1.041

Review 8.  Survival after in-hospital cardiac arrest among cerebrovascular disease patients.

Authors:  Corey R Fehnel; Alissa Trepman; Dale Steele; Muhib A Khan; Brian Silver; Susan L Mitchell
Journal:  J Clin Neurosci       Date:  2018-05-19       Impact factor: 1.961

Review 9.  Arginine vasopressin receptor signaling and functional outcomes in heart failure.

Authors:  Melissa A Wasilewski; Valerie D Myers; Fabio A Recchia; Arthur M Feldman; Douglas G Tilley
Journal:  Cell Signal       Date:  2015-07-30       Impact factor: 4.315

10.  β-adrenergic receptor-mediated cardiac contractility is inhibited via vasopressin type 1A-receptor-dependent signaling.

Authors:  Douglas G Tilley; Weizhong Zhu; Valerie D Myers; Larry A Barr; Erhe Gao; Xue Li; Jianliang Song; Rhonda L Carter; Catherine A Makarewich; Daohai Yu; Constantine D Troupes; Laurel A Grisanti; Ryan C Coleman; Walter J Koch; Steven R Houser; Joseph Y Cheung; Arthur M Feldman
Journal:  Circulation       Date:  2014-09-09       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.